FGFR3 and chondrodysplasia: In the present study, we evaluated the efficacy of TYRA-300, an FGFR3 isoform–selective inhibitor that may potentially provide a larger therapeutic window (31), in wild-type mice and 2 mouse models of FGFR3-driven chondrodysplasia.